Back to Results

Nyxoah SA (NYXH)

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA). Its principal product is the Genio system, a CE-marked, minimally invasive hypoglossal neurostimulation therapy designed for adults with moderate to severe OSA. Incorporated in 2009, Nyxoah is headquartered in Mont-Saint-Guibert, Belgium. The company’s common stock is listed on the NASDAQ under the symbol NYXH.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-NYXH
$1.36
68.5% Upside
Bargain
$2.80
245.8% Upside
Bargain
Fair
0.0%
0.9x
3.6x
86.024 M
44.832 M
44.8%
50.7%
-3.4
77.0%
Valuation • Fair Value

Nyxoah SA (NASDAQ-NYXH) Fair Value by Valuation Model

Review the available estimates for Nyxoah SA (NASDAQ-NYXH), including Comps Fair Value.

Primary Valuation Read

Fair Value

$1.36

Estimated upside of 68.5% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$1.36

Comparable-company valuation reference.

Analyst Price Target

$2.80

Analysts imply upside of 245.8%.

How to read these valuation models

Use the 4 available valuation references for Nyxoah SA (NASDAQ-NYXH) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Nyxoah SA (NASDAQ-NYXH)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

24.738 M

Current operating scale indicator.

Revenue Forecast

37.731 M

Forward revenue estimate.

EBITDA

-94.489 M

Current operating profitability reference.

EBITDA Forecast

-81.416 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Nyxoah SA (NASDAQ-NYXH) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Nyxoah SA (NASDAQ-NYXH)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

-0.79

Higher caution zone on this screen.

Altman Z-Score

-3.4

Lower score that deserves closer risk review.

FCF / Net Income

77.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Nyxoah SA (NASDAQ-NYXH). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Nyxoah SA (NASDAQ-NYXH)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Nyxoah SA (NASDAQ-NYXH). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Nyxoah SA (NASDAQ-NYXH) Stock Forecast & Technical Outlook

Review Nyxoah SA (NASDAQ-NYXH) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Nyxoah SA (NASDAQ-NYXH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Nyxoah SA (NASDAQ-NYXH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Nyxoah SA (NASDAQ-NYXH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Nyxoah SA (NASDAQ-NYXH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Nyxoah SA (NASDAQ-NYXH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Nyxoah SA (NASDAQ-NYXH)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Nyxoah SA (NASDAQ-NYXH) has a Buy consensus, with 2 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 2
Sell 0
FAQ • Fast Investor Answers

Nyxoah SA (NASDAQ-NYXH) Stock FAQ

Data-supported answers about Nyxoah SA (NASDAQ-NYXH), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.36
Estimated upside 68.5%
Valuation Rating
Undervalued
Estimated upside of 68.5%
Analyst Target
$2.80
Implied upside 245.8%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Nyxoah SA (NASDAQ-NYXH) is $1.36. This implies an estimated upside of 68.5% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 68.5% versus the current market price.

The available analyst price target for Nyxoah SA (NASDAQ-NYXH) is $2.80. The analyst target implies estimated upside of 245.8%.

The current financial health read for Nyxoah SA (NASDAQ-NYXH) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Nyxoah SA (NASDAQ-NYXH).

The current market capitalization listed for Nyxoah SA is 86.024 M.

The current enterprise value listed for Nyxoah SA is 44.832 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Nyxoah SA is NASDAQ-NYXH, and the stock is listed on NASDAQ.

Nyxoah SA (NASDAQ-NYXH) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Nyxoah SA is 44.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Nyxoah SA is 50.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABT NYSE Abbott Laboratories Fair Value Fair Market Cap 196.7 B
ISRG NASDAQ Intuitive Surgical Inc Fair Value Fair Market Cap 162.4 B
MDT NYSE Medtronic PLC Fair Value Fair Market Cap 128.3 B
SYK NYSE Stryker Corporation Fair Value Fair Market Cap 127.6 B
BSX NYSE Boston Scientific Corp Fair Value Undervalued Market Cap 64.704 B
BDX NYSE Becton Dickinson and Co Fair Value Fair Market Cap 58.168 B
EW NYSE Edwards Lifesciences Corp Fair Value Fair Market Cap 57.971 B
IDXX NASDAQ IDEXX Laboratories Inc Fair Value Fair Market Cap 52.86 B
MDLN NASDAQ Medline Inc Fair Value Fair Market Cap 52.302 B
GEHC NASDAQ GE HealthCare Technologies Inc Fair Value Fair Market Cap 37.867 B
ALC NYSE Alcon AG Fair Value Fair Market Cap 37.14 B
RMD NYSE ResMed Inc Fair Value Fair Market Cap 33.661 B
DXCM NASDAQ DexCom Inc Fair Value Undervalued Market Cap 31.503 B
PHG NYSE Koninklijke Philips NV ADR Fair Value Fair Market Cap 30.181 B
STE NYSE STERIS plc Fair Value Fair Market Cap 24.777 B
ZBH NYSE Zimmer Biomet Holdings Inc Fair Value Fair Market Cap 20.222 B
SOLV NYSE Solventum Corp Fair Value Fair Market Cap 14.84 B
SNN NYSE Smith & Nephew SNATS Inc Fair Value Undervalued Market Cap 13.319 B
BAX NYSE Baxter International Inc Fair Value Fair Market Cap 13.27 B
GKOS NYSE Glaukos Corp Fair Value Overvalued Market Cap 13.016 B